Department of Pediatrics, University of Colorado School of Medicine, Colorado.
Department of Epidemiology, Center for Global Health, Colorado School of Public Health, Colorado.
J Infect Dis. 2020 Mar 28;221(8):1256-1270. doi: 10.1093/infdis/jiz278.
Respiratory syncytial virus (RSV) is the primary cause of respiratory tract infections in infants; however, current burden estimates report only the short-term effects of acute infection.
Infants with RSV infection and ≥24 months of continuous enrollment were retrospectively identified from the Truven MarketScan database (1 January 2004-30 September 2015). Exposed infants (n = 38 473) were propensity score matched to nonexposed controls (n = 76 825) by baseline characteristics and gestational age. Five-year cumulative all-cause, asthma/wheezing, and respiratory event-related hospitalization rates and physician and emergency department healthcare-resource utilization rates were assessed.
During follow-up, RSV-infected cohorts had higher average all-cause cumulative hospitalization rates, compared with controls, with values of 79.9 hospitalizations/100 patient-years (95% confidence interval [CI], 41.7-118.2) for 213 early premature infants (P < .001), 18.2 hospitalizations/100 patient-years (95% CI, .8-35.7) for 397 premature infants (P = .04), 34.2 hospitalizations/100 patient-years (95% CI, 29.1-39.2) for 4446 late premature infants (P < .001), and 16.1 hospitalizations/100 patient-years (95% CI, 14.9-17.4) for 33 417 full-term infants (P < .001). Cumulative rates of physician and emergency department visits were also higher for RSV-infected infants. Asthma/wheezing accounted for 10%-18% of total 5-year physician visits.
Infant RSV infection has a significant long-term healthcare-resource utilization impact across gestational ages for at least 5 years after infection, most of it in the first 2 years. Systematically collecting healthcare-resource utilization data will be important for cost-effectiveness evaluations of RSV interventions in planned or ongoing trials.
呼吸道合胞病毒(RSV)是婴儿呼吸道感染的主要病原体;然而,目前的负担估计仅报告了急性感染的短期影响。
从 Truven MarketScan 数据库(2004 年 1 月 1 日至 2015 年 9 月 30 日)中回顾性确定 RSV 感染且连续入组≥24 个月的婴儿。根据基线特征和胎龄,将暴露婴儿(n=38473)与非暴露对照(n=76825)进行倾向评分匹配。评估 5 年全因、哮喘/喘息和呼吸道相关住院率以及医生和急诊就诊的医疗资源利用率。
在随访期间,与对照组相比,RSV 感染组的全因累积住院率更高,213 例早产早期婴儿的平均住院率为 79.9 例/100 患者年(95%置信区间 [CI],41.7-118.2)(P<.001),397 例早产儿的住院率为 18.2 例/100 患者年(95%CI,0.8-35.7)(P=.04),4446 例晚期早产儿的住院率为 34.2 例/100 患者年(95%CI,29.1-39.2)(P<.001),33417 例足月婴儿的住院率为 16.1 例/100 患者年(95%CI,14.9-17.4)(P<.001)。RSV 感染婴儿的医生和急诊就诊次数也较高。哮喘/喘息占 5 年总就诊次数的 10%-18%。
婴儿 RSV 感染对至少 5 年的医疗资源利用率有重大的长期影响,其中大部分发生在感染后的前 2 年。在计划或正在进行的试验中,系统收集医疗资源利用数据对于 RSV 干预措施的成本效益评估将非常重要。